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Abstract
Introduction: Our aim was to investigate the possibility 
of a significant relationship between chemokines 
and chemokine receptor genes polymorphisms and 
the spontaneous clearance or the persistence of HCV 
infection.
Methods: A total of 96 hemodialysis (HD) patients 
infected with HCV were classified into two groups: G1 
included 73 patients with persistently positive HCV-RNA 
and G2 included 23 HD patients who have spontaneously 
eliminated the virus.  The control group consisted of 170 
healthy blood donors. All subjects were genotyped for 
CCR5 Δ32, CCR5 (-59029) A/G, CCR2 (64Ile) and 
MCP-1(-2518) A/G gene polymorphisms. 
Results: Our results showed statistically significant 
increased frequencies of the CCR2 (64Ile) and the 
(-59029) CCR5 A alleles in patients infected with HCV 
(22.1% and 35.9%) compared to G1 (24.3% and 40.6%) 
and compared to controls (14.4% and 20%). We also 
observed a lower frequency of the MCP-1 G allele and a 
greater frequency of the CCR5Δ32 variant in G2 (15.2% 
and 6.5%) compared to G1 (22.6% and 1.4%) that was 
not statistically significant. However, adjustment for 
known covariates (age, gender and HCV genotypes) 
didn’t confirm the results of univariate analysis. 
Conclusion: In conclusion, our study suggests a possible 
role for some of the studied chemokines polymorphisms 
in the spontaneous clearance or persistence of HCV 
infection in Tunisian population. These results should be 
further investigated by a prospective cohort studies and 
large population-based studies.
Keywords: Chemokines; Receptors; Hepatitis C virus; 
Spontaneous Clearance; Polymorphisms.
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Introduction
Hepatitis C virus (HCV) is the major cause of post 
transfusion hepatitis. HCV infection becomes chronic 
in about 80% of infected individuals and often leads 
to serious consequences, including liver cirrhosis and 
hepatocellular carcinoma (HCC) [1, 2]. Only 20% of 
infected subjects clear the virus spontaneously [3]. Studies 
of early HCV infection suggest that a vigorous CD4+ T 
cells response is associated with viral clearance [4-6]. In 
contrast, patients developing a chronic infection show 
a predominant Th2 response [7-9]. Interplay between 
chemokines and their receptors is considered crucial 
for transmigration of lymphocytes and monocytes from 
the circulation to the liver portal area of inflammation 
during viral hepatitis, including HCV induced hepatitis. 
Differences in chemokine receptor expression between 
Th1 and Th2 cells might explain the regulating T helper 
cell polarization and their selective recruitment to liver 
tissue [10, 11]. Among these inflammatory molecules, 
monocyte chemoattractant protein-1 (MCP-1) with the 
corresponding chemokine receptors CCR2 and CCR5, 
specific receptor for pro-inflammatory chemokines: 
Rantes, MIP-1α and MIP-1β, are likely to be responsible 
for mononuclear cell accumulation in progressive of liver 
injury. Several allelic variants of these proteins have 
been shown to be important in the pathogenesis viral 
infection, either by modulating virological response or 
by influencing the severity of liver injury [12-14]. 
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A bi-allelic G/A polymorphism at position -2518 of the 
MPC-1 gene, relative to the major transcriptional start 
site, has been described and was shown to influence the 
level of MCP-1 production in response to inflammatory 
stimuli [15].
CCR5 and CCR2 are two of a cluster of six chemokine 
receptor genes mapped to 3p21. A substitution mutation 
resulting in a valine (Val) to isoleucine (Ile) designed 
CCR2 (64Ile), a 32-bp deletion in the CCR5 gene leading 
to a non-functional protein and CCR5 promoter single 
nucleotide polymorphisms (SNP) were identified. Both 
CCR mutations have been implicated in the pathogenesis 
of human immunodeficiency virus (HIV) infection and 
the presence of the muted allele confers varying degree 
of anti-HIV protection that is reflected in slower disease 
progression [16]. Several studies have examined these 
polymorphisms in association with HCV and HIV 
infections [17-19].
The aim of this study was to investigate the distribution 
of the wild type and mutant alleles of MCP-1 -2518, 
CCR5-Δ32, CCR5-59029 and CCR2 (64Ile) in HCV 
infected  hemodialysis Tunisian patients in comparison 
with healthy controls. Furthermore, we have analyzed 
the association of particular genotypes with outcomes 
of HCV infection, in terms of viral clearance or viral 
persistence. 
Methods
Subjects: This is a retrospective study which involved 
96 HCV infected individuals with confirmed antibody 
positivity to HCV. They were negative for hepatitis B 
surface antigen (HBsAg) and HIV infection. All patients 
were dialyzed during 2004 at different hemodialysis (HD) 
centers (private and public) in various regions of Tunisia. 
They were divided into two groups. Group I (G1) included 
73 patients with persistent HCV infection as assessed by 
two positive PCR tests for HCV-RNA separated by more 
than one year. Group II (G2) consisted of 23 subjects 
considered to have spontaneously recovered from 
HCV infection on the basis of two negative PCR tests 
for HCV-RNA one year apart. None of the patients had 
received treatment for HCV infection before entering the 
study. Data obtained from each patient at the HD center 
included age at diagnosis, gender and possible risk factors 
for HCV (such as blood transfusion, invasive procedures 
or intravenous drug abuse). These two groups of patients 
were comparable in viral characteristics and average 
duration on HD (Table-1). In addition, blood samples 
were obtained from 170 ethnical and geographically 
matched healthy individuals who tested negative for 
HBsAg, HIV-Ab and HCV-Ab. These 170 subjects 
served as controls. The study was approved by the ethics 
committee of Charles Nicolle Hospital (Tunis, Tunisia) 
and all participants gave informed consent to participate 
in the study.
HCV RNA detection: HCV-RNA in serum was detected 
by reverse transcriptase PCR (Inno-Lipa HCV II, 
Innogenetics Belgium) according to the manufacturer’s 
instructions. Patients who were HCV-PCR positive on 
the initial assessment and became consistently HCV-PCR 
negative were classified in G2.
Typing HCV: HCV genotypes were determined by means 
of inverse hybridization using specific oligonucleotide 
probes assay (HCV Genotype Assay Lipa, Innogenetics 
Belgium) according to the manufacturer’s instructions.
DNA Extraction: Blood samples were collected on 
EDTA, and DNA was isolated by the Salting-Out method 
reported by Miller et al [20].
MCP-1 promoter genotyping: The identification of 
polymorphism was carried out using PCR, followed 
by a restriction fragment length polymorphism (RFLP) 
assay, using PvuII site which is introduced by the 
presence of the G nucleotide. The regulatory region 
of the MCP1 gene (-1817 to -2746) was amplified 
by PCR resulting in 930 bp fragment. Primers used 
were 5’CCGAGATGTTCCCAGCCAG-3’ (forward) 
and 5’-CTGCTTTGCTTGTGCCTCTT-3’ (reverse). 
1µl of genomic DNA (~100ng) were added to 19µl of 
amplification buffer containing 11µl of H2O, 4µl of 5x 
PCR buffer, 1.6µl of MgCl2 (2mM), 0.4µl of dNTPs 
(0.2mM), 0.1 µl of Taq DNA polymerase (0.5U) and 
5µM of each forward and reverse primers. PCR was run 
for 40 cycles using the following temperature profile: 
denaturation at 94°C for 60s, annealing at 55°C for 60s, 
extension at 72°C for 1min and 30s, followed by a single 
final extension step at 72°C for 10min. 4µl of the PCR 
products were digested with 5U of PvuIIin 10x buffer 
and H2O up to a final volume of 20µl at 37°C for 2h 
and 30min. The resulting products were separated by gel-
electrophoresis in 1.5% agarose gel. Samples showing 
only a 930bp were assigned as AA, samples showing 
two bands of 708bp and 222bp were considered GG and 
samples showing three bands 930, 708 and 222bp were 
typed AG.
CCR5-59029 genotyping: CCR5-59029 genomic variants 
were detected by using RFLP-PCR. The presence of the G 
nucleotide at position -59029 of the CCR5 gene creates a 
recognition site for the BspI286I enzyme. Primers used were 
5’-CCCGTGAGCCCATAGTTAAAACTC-3’ (forward) 
and 5’-TCACAGGGCTTTTCAACAGTAAGG-3’ 
(reverse). 2µl of genomic DNA (~100ng) were added to 
18µl of amplification buffer containing 11.8µl of H2O, 
4µl of 5x PCR buffer, 1.2µl of MgCl2 (1.5mM), 0.35µl 
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of dNTPs (0.175mM), 0.1 µl of Taq DNA polymerase 
(0.5U), 10µM of each forward and reverse primers. PCR 
was run for 35 cycles using the following temperature 
profile: a single initial denaturation at 94°C for 4min, 
denaturation at 94°C for 30s, annealing at 55°C for 45s, 
extension at 72°C for 1min, followed by a single final 
extension step at 72°C for 7min. 5µl of the PCR products 
were digested with 3U of BspI286I in 10x buffer and 
H2O up to a final volume of 20µl at 37°C for 1 night. The 
resulting products were separated by gel-electrophoresis 
in 2% agarose gel. Samples showing only a 130bp were 
assigned as GG, samples showing only 258bp band were 
considered AA and heterozygote have both bands.
CCR2 (64Ile) genotyping: For characterization of the 
CCR2 polymorphism, sequence specific primer PCR 
was used (SSP-PCR). The first primer was specific for 
the wild type allele sequence. The second primer was 
specific for the sequence of the mutant allele. In the 
case of homozygous wild type individual (+/+), the 
product was observed only in the first reaction. In the 
case of a homozygous mutant individual (64Ile/64Ile), 
the product was detected only in the second reaction. 
When the typed proband was heterozygous (+/64Ile), 
the product were detected in both the wild and the 
mutant specific reaction. Primers used were CCR2 440 
5’-GTGGGCAACATGCTGGTCA-3’, CCR2441 5’-
CCCAAAGACCCACTCATTTG-3’, and CCR2 442 
5’-GTGGGCAACATGCTGGTCG-3’. 1µl of genomic 
DNA (~100ng) was added to 14µl of amplification buffer 
containing 7.5µl of H2O, 3µl of 5x PCR buffer, 1.2µl of 
MgCl2 (2mM), 0.3µl of dNTPs (0.2mM), 0.05 µl of Taq 
DNA polymerase (0.25U) and 5µM of each primer. PCR 
was run for 5 cycles using a single initial denaturation 
at 94°C for 1min, 5 cycles of denaturation at 96°C for 
25s,  annealing at 65°C for 50s, extension at 72°C for 
45s, 21 cycles of denaturation at 96°C for 25s,  annealing 
at 70°C for 45s, extension at 72°C for 45s, and 4 cycles 
of denaturation at 96°C for 25s, annealing at 55°C for 
60s, extension at 72°C for 2min.
CCR5Δ32 genotyping: CCR5Δ32 genotype was 
determined by sizing PCR amplicons that include the 
entire region of the deletion. PCR was conducted in 
15µl reaction containing 0.5µl of genomic DNA (50ng), 
5µM of each primer, 0.25µl of dNTPs (0.175Mm), 0.9µl 
of MgCl2 (1.5mM), 3µl of 5xPCR buffer and 0.1 µl of 
Taq DNA polymerase (0.5U). Thermocycling procedure 
consisted of initial denaturation at 94°C for 4min, followed 
by 35 cycles of 94°C for 30s, 52°C for 45s, 72°C for 
7min; amplicons were visualized in 2% agarose gel. The 
sense primer was 5’-TGTTTGCGTCTCTCCCAG-3’, 
and antisense was 5’-CACAGCCCTGTGCCTCTT-3’, 
which result in a 233bp product for the wild type amplicon 
(+/+) and 201 bp for the deletion product (Δ32/Δ32).
Statistical methods: Genotypes and alleles frequencies 
were calculated using Epi-stat program (version 6; center 
for disease control and prevention [CDC], Atlanta, 
GA). Statistical comparisons between different groups 
of patients and controls was conducted by the χ² test 
calculated on 2x2 contingency tables. Fisher exact test 
was used when an expected cell value was less than 5. P 
value < 0.05 was considered statistically significant. The 
strength of the association between genotypes or alleles 
in each group was estimated by calculating of the odds 
ratios (OR) and 95% confidence intervals (CI) using the 
same software. Logistic regression models were built 
with clearance of HCV infection (RNA-HCV negative) 
as the response variable to estimate adjusted ORs.
Results
Epidemiological characteristics
Clinical and virological characteristics are summarized 
in Table-1. Our results showed that 1b genotype was 
the predominant genotype among G1 (64.4%) and G2 
(70%). The prevalence of risk factors was similar in both 
groups. None of the patients was an intravenous drug 
user. Ninety patients (93.7%) had history indicating risk 
of exposure to HCV due to blood transfusion (56.3%) or 
due to surgical or medical invasive procedures (37.5%). 
No significant differences were found in the distribution 
according to regions, private versus public nature of the 
HD centers or the duration of HD between the two groups 
of patients. 
Genetic polymorphisms
All analyzed allele frequencies and genotype distributions 
were in Hardy-Weinberg equilibrium both in patients and 
controls. All polymorphism frequencies are described 
below and summarized in Table-2.
MCP-1 gene polymorphism: Comparison of allele 
frequencies in patients infected with HCV and controls 
did not reveal significant difference for the MCP-1 gene 
polymorphism. Nevertheless, the frequency of genotype 
GG was lower in patients (5.2%) than in controls (17%). 
Regarding the two groups of HD patients, there was 
an increased frequency of the G allele in G1 (22.6%) 
compared with G2 (15.2%) but the difference did not 
reach statistical significance.
CCR2 (64Ile) gene polymorphism: Significant 
differences were found between HCV infected 
patients and controls regarding the CCR2 (64Ile) gene 
polymorphism. The frequency of the +/+ genotype 
was significantly higher in controls (73.5%) compared 
to HCV infected patients as a whole (60%) and to G1 
patients (56.9%) [P = 0.03; OR = 1.9; CI 95% = 1.3-2.7, 
and P = 0.02; OR = 2.1, CI 95% = 1.1-3.9 respectively]. 
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On the other hand, the frequency of the +/64Ile genotype 
was significantly increased in the HCV infected patients 
group as a whole (35.8%) and in G1 (37.5%) compared to 
controls (24.1%) [P = 0.04; OR = 0.6; CI 95% = 0.3-1.0; 
P = 0.05; OR = 0.5; CI 95% = 0.3-1.0 respectively]. The 
distribution of allele frequencies showed a significantly 
increased frequency of the 64Ile allele in HCV infected 
patients group (22.1%) and in G1 (24.3%) compared to 
controls (14.4%) [P = 0.03; OR = 0.6; CI 95% = 0.4-1.0 
and P = 0.09; OR = 0.5; CI 95% = 0.3-0.9 respectively]. 
The comparison of these frequencies according to the 
evolution of HCV infection also revealed an increased 
frequency of the 64Ile allele in G1 (24.3%) compared 
to G2 (15.2%). However, this difference did not attain 
statistical significance.
CCR5-59029 gene polymorphism: The AA CCR5-59029 
genotype occurred more frequently among HCV infected 
patients and G1 compared to controls (35.9 and 40.6% 
versus 20%) [P = 0.01; OR = 0.5, CI 95% = 0.3-0.8 and 
P = 0.002; OR = 0.4; CI 95% = 0.2-0.7 respectively]. 
The frequency of the AG CCR5-59029 genotype 
was decreased in G1 compared with controls (36.2% 
versus 52.4%) [P = 0.03, OR = 1.9, CI 95% = 1.1-3.6]. 
Comparison of allele frequencies showed an increased 
frequency of the A allele in HCV infected patients group 
(56%) and in G1 (58.7%) compared to controls (46.2%) 
[P = 0.04; OR = 0.7; CI 95% = 0.5-1.0 and P = 0.02; 
OR = 0.6; CI 95% = 0.4-0.9 respectively]. The comparison 
of these frequencies between the two groups of patients 
revealed a non significant higher frequency of the A allele 
in G1 (58.7%) compared to G2 (47.8%).
CCR5 Δ32 gene polymorphism: No significant 
differences in the genotype distribution or in allele 
frequencies were observed between patients infected 
with HCV and controls. No homozygous mutant CCR5 
Δ32 subjects were detected in either the control group 
or G1.When transmission of these genetic variants was 
analyzed in the two groups of HD patients, the Δ32 variant 
was present at a greater frequency in G2 compared  to 
G1 (6.5% versus 1.4%), but this difference did not reach 
statistical significance.
Haplotype distribution: The allelic distribution of the 
CC-chemokine G MCP-1-2518 in combination with the 
corresponding chemokine receptor CCR2 (64Ile) did 
not differ significantly between patients and controls 
nor between G1 and G2. The same applies for the other 
haplotype associations: A(-59029)CCR5/64IleCCR2, 
A(-59029)CCR5/CCR5Δ32 and CCR5Δ32/64IleCCR2 
(Data not shown). After adjustment for age, gender and 
HCV genotypes as confounders, multivariate analysis 
did not reveal any statistical association for the alleles 
and genotype frequencies studied.
Discussion
This study showed an association between chemokines/
chemokine receptors and the outcomes of HCV infection 
in Tunisian HD patients. Our results suggested a possible 
role for the -2518 MCP-1 G allele in the persistence of 
HCV infection. We speculate that individuals bearing 
G at position -2518 produce more MCP-1 protein than 
individuals with A allele. In consequence, they could 
have a stronger inflammatory response with higher liver 
tissue damage. Our results, which indicated an increased 
prevalence of -2518 G allele in G1 patients compared to 
G2, are in agreement with this hypothesis. Indeed, Rovin 
et al reported that in vitro cells obtained from GG or 
GA subjects produce more MCP-1 molecule than those 
isolated from AA individuals [15]. On the other hand, 
HCV infected patients with the -2518 MCP-1 G allele 
were reported to be more prone to hepatic inflammation 
and fibrosis [21]. The same higher level variant G allele 
was suggested to contribute in the chronicity of HBV 
infection in Korean population [22]. However, the wide 
CI in many of our findings reflects the relatively small 
Table 1:  Clinical and virological characteristics of the study 
subjects
Characteristics G1 (n = 73) G2 (n = 23)
Gender ratio (Male/Female) 33/40 13/10
Mean age (years) 58 ± 13.08 55.5 ± 11.7
HCV genotype: n (%)*
     1a 2 (2,6) -
     1b 47 (64.4) 7 (70%)
     2a/2c 7 (9.2) 1 (10%)
     4 14 (18.4) 2 (20%)
     1b/4 3 (4) -
Risk factors: n (%)
     Blood transfusion 40 (64.8) 14 (60.8)
     Invasive procedure 29 (39.7) 7 (30.4)
     Intravenous drug abuse 0 0
Regional distribution: n (%)
     Tunis (Capital region) 62 (84.9) 23 (100)
     North 10 (13.7) 0
     Central 0 0
      South 1(1.3) 0
HD in private sector: n (%) 64 (87.7) 18 (78.26)
HD in public sector: n (%) 9 (12.3%) 5 (21,7)
Mean duration on HD (months) 158.1 ± 58 164 ± 60.21
* HCV genotype was determined for only 10 patients in G2 who 
were HCV-RNA positive at baseline and spontaneously cleared HCV 
infection as suggested by two subsequent negative HCV-PCR detections 
one year apart.
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Table 1:  MCP1, CCR2 and CCR5 genotype and allele frequencies in patients and controls
Polymorphisms Controls Total Patients G1 G2
N % N % N % N %
MCP1-2518
Genotype
AA 91 53 61 63.5 45 61.6 16 69.6
AG 67 40 30 31.3 23 31.5 7 30.4
GG 12 17 5 5,2 5 6.9 0 0
Allele
A 146 73.2 152 79.2 113 77.4 39 84.8
G 91 26.8 40 20.8 33 22.6 7 15.2
CCR2 (64Ile)*
Genotype
+/+† 125 73.5 57 60 41 56.9 16 69.6
+/64Ile‡ 41 24.1 34 35.8 27 37.5 7 30.4
641/64Ile 4 2.4 4 4,2 4 55.6 0 0
Allele
+ 291 85.6 148 77.9 109 75.7 39 84.8
64Ile§   49 14.4   42 22.1   35 24.3   7 15.2
CCR5 Δ32
Genotype
+/+ 162 95.3 92 95.8 71 97.3 21 91.4
+/ Δ32 8 4.7 3 3.1 2 2.7 1 4.3
Δ32/ Δ32 0 0 1 1.1 0 0 1 4.3
Allele
+ 332 97.6 187 97.4 144 98.6 43 93.5
Δ32 8 2.4 5 2.6 2 1.4 3   6.5
CCR5 59029 ||
Genotype
GG 47 27.6 22 23.9 16 23.2 6 26
AG¶ 89 52.4 37 40.2 25 36.2 12 52.2
AA** 34 20 33 35.9 28 40.6 5 21.8
Allele
G 183 53.8 81 44 57 41.3 24 52.2
A†† 157 46.2  103 56 81 58.7 22 47.8
*   Only 95 total patients were tested for CCR2 (64Ile) (72 in G1 and 23 inG2).
†   The homozygous +/+ CCR2 (64Ile) genotype was significantly higher in controls than in total patients group and in G1 HCV patients [P = 0.0; 
OR = 1.9; CI 95% = 1.3-2.7 and P = 0.02; OR = 2.1, CI 95% = 1.1-3.9]. 
‡   The heterozygous +/64Ile CCR2 (64Ile) genotype was significantly increased in patients group and in G1 versus controls [P = 0.043; OR = 0.6; 
CI 95% = 0.3-1.02; P = 0.049; OR = 0.5; CI 95% = 0.3-1.0].
§  Comparing CCR2 (64Ile) allele frequency in total patients group and G1with controls [P = 0.03; OR = 0.6; CI 95% = 0.4-1.0 and P = 0.09; 
OR = 0.5; CI 95% = 0.3-0.9].
||    Only 92 total patients were tested for (-59029)CCR5 A/G (69 in G1 and 23 in G2).
¶    The frequency of (-59029) CCR5AG genotype was significantly lower in G1compared to controls [P = 0.03, OR = 1.9, CI 95% =1.1-3.6].  
**  The frequency of (-59029) CCR5 AA genotype was significantly higher in total patients group and G1 compared to controls [P = 0.01; OR = 0.5, 
CI 95% = 0.2-0.8 and P = 0.0017; OR = 0.4; CI 95% = 0.2-0.7].  
†† Comparing (-59029) CCR5 A allele frequency in total patients group and G1 with controls [P = 0.04; OR = 0.7; CI 95% = 0.5-1.0 and P = 0.02; 
OR = 0.6; CI 95% = 0.4-0.9].
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number of patients, particularly in G2, with a consequent 
loss of statistical power. Another study that includes a 
greater number of patients who have spontaneously 
recovered from HCV infection would be required to 
verify this association. CCR2 signaling promotes Th1 
development in infection models. Indeed, Traynor et 
al reported that CCR2 knock out mouse have 46% 
reduction in lymphocyte recruitment to sites of infection 
and inflammation and 80% reduction in CD4+T cells 
locally [23].Our study showed a significant association 
of the CCR2 (64Ile) allele with susceptibility to HCV 
infection and persistence of infection This variant was 
significantly increased in patients infected with HCV and 
in G1 compared to controls. In addition, this allele was 
more represented in persistent HCV infection group than 
in the clearance group. This is in agreement with results 
reported by Mascheretti et al, which showed that the 
CCR2 (64Ile) variant was under-represented in patients 
with spontaneous viral elimination compared to patients 
suffering from chronic infection, and that the frequency of 
the homozygous variant genotype was higher in patients 
who cleared the virus compared to both patients with 
persistent infection and controls in a German study [21]. 
This genetic variant has also been related to the onset of 
a variety of autoimmune/inflammatory diseases such as 
familial multiple sclerosis, pulmonary sarcoidosis, type 1 
diabetes mellitus, asthma and inflammatory bowel disease 
[24]. In the majority of these studies, this genetic CCR2 
variant has been found to be associated with a milder 
course and/or a reduced risk of developing diseases. In 
our study, the association between HCV persistence and 
CCR2 (64Ile) allele may reflect the same process with a 
reduction in the function of CCR2 in the HCV immune 
response and disease persistence. On the other hand, this 
polymorphism represents a conservative change in the 
first transmembrane domain of the protein. The receptor 
containing the variance has been shown to be expressed 
efficiently on the cell surface. Its signal transcription in 
response to MCP-1 binding and protein expression is 
not altered. This hypothesis could explain the defect of 
statistical association between haplotype G MCP1(-2518)/
CCR2(64Ile) and the outcome of HCV infection in our 
studied population. Previous studies have established that 
A(59029)CCR5 allele had higher promoter activity than 
G(59029) and could regulate CCR5 gene expression [17, 
25]. This observation is in accordance with our findings 
that reveal a significant association of the CCR5-59029 
A allele with susceptibility to infection and progression 
to chronicity. Chang et al corroborate similar association 
between CCR5-59029 A allele and an increased risk of 
HBV infection in a Korean population [26].
In the CCR5 gene the most studied polymorphism 
was the 32 base pair deletion CCR5 Δ32 that creates 
a truncated protein that fails to reach the cell surface. 
Patients homozygous for this mutation cannot express 
CCR5 on the cell surface, whereas the heterozygous 
state results in decreased expression of the functional 
CCR5 protein [27]. In an Irish study, the heterozygote 
CCR5 Δ32 was associated with spontaneous clearance 
of HCV infection [19]. In agreement with this report, 
Hellier et al found an association between CCR5 Δ32 and 
reduced portal inflammation and milder fibrosis in a large 
European cohort [28]. Interestingly, CCR5Δ 32 carriers 
showed significantly reduced response rates to anti HCV 
interferon therapy [29, 30].
In accordance with cited studies, we observed a protective 
effect of this variant in our study. The Δ32 variant was 
more frequent in the cleared HCV infection group 
compared to the chronically infected group. The lack 
of statistical significance observed here might be due to 
the small size of our cohort, particularly the spontaneous 
clearance group.
Because the CCR2 and CCR5 genes are closely located 
on the chromosome 3p21, we suggest that the haplotype 
associations CCR5(-59029)A/CCR264Ile, CCR5(-59029)
A/CCR5Δ32 and CCR5Δ32/CCR264Ile, combining 
the different genetic variants, may be important  in  the 
persistence of HCV infection.
Because of the small size of our cohort and the 
retrospective nature of the study, it should be considered 
an exploratory study and our results must be treated 
with caution. Future studies are needed to confirm 
these chemokine/chemokine receptor polymorphism 
associations with HCV infection progression and to 
further clarify their mechanism of action.
Conclusion
In conclusion, this study has attempted to elucidate 
the role of CC chemokines and their receptors in the 
persistence or clearance of HCV infection. Our data 
suggests that the CCR5(-59029) A, CCR2 (64Ile) and 
MCP-1(-2518) G allele profiles predispose to persistent 
HCV infection. They may be part of the spectrum of 
immunogenetic factors involved in chronic HCV disease 
in Tunisian population.
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